Perhaps even more remarkably, in a cohort of 80 pediatric and adult patients with various karyotypes, FLT3-ITD status at relapse was associated with TTR more significantly than the same molecular feature at diagnosis [79], and among 69 patients with pediatric AML and mixed cytogenetics, FLT3-ITD and WT1 mutations at relapse, but not at presentation, were significantly associated with shorter OS, with FLT3-ITD status at relapse confirmed as an independent prognostic parameter in multivariate analyses [83]. The gene discussed is FLT3; the disease is acute myeloid leukemia.